Neurofibromatosis Tumor Burden Assessment

Quantify plexiform neurofibroma burden in NF1 using volumetric MRI measurements to assess eligibility for selumetinib and monitor treatment response in pediatric and adult patients.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Quantify plexiform neurofibroma burden in NF1 using volumetric MRI measurements to assess eligibility for selumetinib and monitor treatment response in pediatric and adult patients

Each component has a specific meaning:

  • Volumetric MRI measurements — The volumetric mri measurements recorded for the scenario being assessed.

Note: Interpret the nf1 tumor burden result against the thresholds and context described above.

How to Use

Enter the volumetric MRI measurements for the scenario you are assessing. Quantify plexiform neurofibroma burden in NF1 using volumetric MRI measurements to assess eligibility for selumetinib and monitor treatment response in pediatric and adult patients. Use the nf1 tumor burden result to inform your calculation.

Frequently Asked Questions